Kuala Lumpur, Malaysia – ALPS Global Holding Berhad has been officially recognised as a key contributor to MyPRICISE (Malaysian Prioritisation of Vaccine Selection), a national initiative led by the Ministry of Health Malaysia to support strategic, data-driven vaccine evaluation for the country.
As documented in the MyPRICISE Calculation Manual, Professor Manickam Ravichandran, representing ALPS, joined a consortium of Malaysia’s top institutions in co-developing the framework—alongside experts from the University of Malaya, Malaysian Genome & Vaccine Institute, Pharmaniaga Berhad, and others.
Empowering Data-Driven Vaccine Decision-Making
MyPRICISE is a landmark public health tool that helps Malaysian authorities assess vaccine candidates through a robust, evidence-based scoring system. It evaluates each vaccine across six weighted domains:
- National Vaccine Policy Alignment
- Market Attractiveness
- Technology Advancement
- Economic Considerations
- Ecosystem Readiness
- Scientific and Clinical Properties
Using these domains, the tool generates a composite score that enables policymakers to prioritise vaccines based on national health needs, cost-effectiveness, and scientific merit.
ALPS’ Strategic Role
ALPS contributed both scientific expertise and policy insight through the participation of Prof. Manickam Ravichandran, who was actively involved in workshops and expert consultations. His efforts helped define parameter weightings, scoring calculations, and the final evaluation model featured in the national manual.
In recognition of this contribution, Prof. Manickam received a Certificate of Appreciation from the Minister of Health, Datuk Seri Dr. Dzulkefly Ahmad, for his role in shaping Malaysia’s future vaccine landscape.
“This initiative reflects our long-term vision of enabling national resilience through science, strategy, and collaboration,” said Prof. Manickam.
Supporting Malaysia’s Healthcare Innovation Ecosystem
ALPS Global Holding Berhad’s involvement in MyPRICISE exemplifies its commitment to public-private partnerships, biomedical innovation, and national healthcare advancement. By contributing to frameworks that influence real-world policy and health outcomes, ALPS continues to play a pivotal role in Malaysia’s biotechnology ecosystem.
